Upgrade to SI Premium - Free Trial

Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)

April 8, 2026 6:55 AM
Guggenheim analyst Seamus Fernandez reiterated a Buy rating and $72.00 price target on Bristol-Myers Squibb Co. (NYSE: BMY).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments